Transient and definitive haematopoiesis in mammals and *Drosophila*
===================================================================

Vertebrate haematopoietic stem cells (HSCs) ensure continuous haematopoietic cell production throughout life. HSCs can be defined by their dual ability to self-renew, thereby maintaining their numbers, and to differentiate into all lineages of the blood and immune system ([@b16-0040439]). Blood cells first appear in the mammalian conceptus, in the extraembryonic yolk sac, concomitant with the developing vasculature. These early haematopoietic progenitors are, however, of more limited potency than adult HSCs. In mice, HSCs that confer complete, long-term, multilineage haematopoietic repopulation of irradiated recipient mice first appear at embryonic day (E)10.5 in the aorta-gonad-mesonephros (AGM) region of the embryo body and the placenta, and they seed the fetal liver and the adult bone marrow. There is a rapid and permanent perinatal shift of the entire haematopoietic system to the bone marrow ([@b46-0040439]; [@b17-0040439]).

The decisions of HSCs to self-renew or differentiate, and to become quiescent or proliferate, are tightly controlled by integrating extrinsic cues provided by the niche. The concept of the niche was coined more than 30 years ago to describe the structural and regulatory microenvironment that sustains long-term renewal of bone marrow HSCs ([@b62-0040439]). Recent studies, including the successful detection of HSCs in the bone marrow of live animals by using real-time imaging technology, support the view that there are two subpopulations of HSCs: one that is quiescent \[also referred to as dormant, reserved or long-term (LT) HSCs\], and the other that is more actively cycling \[also referred to as primed, activated or short-term (ST) HSCs\] ([@b75-0040439]; [@b41-0040439]; [@b77-0040439]). Primed HSCs provide ongoing support for the daily normal regeneration of billions of blood cells, whereas dormant HSCs that have maximal, long-term reconstitution potential are mobilised upon bone marrow injury ([@b75-0040439]; [@b70-0040439]).

Similarly to vertebrates, *Drosophila* haematopoiesis occurs in two spatially and temporally distinct phases ([@b12-0040439]). The *Drosophila* life cycle comprises an embryonic stage, three larval stages and metamorphosis, which gives rise to an adult. The first embryonic phase provides two types of circulating blood cells (haemocytes) -- the plasmatocytes and the crystal cells (see below) -- both of which subsist in the larva either in the haemolymph or attached to the inner epidermis in the case of sessile haemocytes ([@b27-0040439]; [@b28-0040439]). The second phase of haematopoiesis takes place in larvae, in a specialised haematopoietic organ known as the lymph gland (LG), which is situated along the anterior part of the dorsal aorta ([@b36-0040439]) ([Fig. 1A](#f1-0040439){ref-type="fig"}). The LG contains haematopoietic progenitors (pro-haemocytes) for three types of functional haemocytes: first, the plasmatocytes, which are monocyte-like cells involved in phagocytosis of apoptotic bodies and pathogens, and, second, the crystal cells, which are required for melanisation, an insect-specific immune and wound-healing response. These two haemocyte types are released in the haemolymph upon dispersal of the LG at the onset of metamorphosis. The LG also gives rise to a third type of haemocyte, the lamellocytes, which are devoted to encapsulation of foreign bodies that are too large to be phagocytosed. Lamellocytes do not differentiate in normal developmental conditions but only in response to specific immune challenges such as wasp parasitism ([@b61-0040439]; [@b36-0040439]; [@b12-0040439]), stress conditions mediated by an increase of reactive oxygen species (ROS) and mutant backgrounds in which their massive proliferation leads to the formation of 'melanotic tumours' that result from encapsulation of *Drosophila* tissue by lamellocytes (see below).

![**Parallels in haematopoiesis between the *Drosophila* LG and mammalian bone marrow.** (A) Schematic representation of a *Drosophila* third instar larva, illustrating the presence of circulating and sessile haemocytes of embryonic origin, and showing the position of the larval haematopoietic organ (the LG) along the dorsal aorta. T and A refer to thoracic and abdominal segments, respectively, and are numbered along the anterior-posterior axis. (B) The primary lobe of the LG consists of the PSC (blue), the MZ (yellow; containing haemocyte progenitors) and the CZ (red), in which differentiation of plasmatocytes and crystal cells takes place. Lamellocytes only differentiate in response to specific immune threats, at the expense of progenitors. There also exists a population of intermediate progenitors that have left the MZ (found within the orange region). Signalling pathways that are active in the PSC and MZ are indicated. Tightly controlled levels of ROS sensitise haemocyte progenitors to differentiation. Unpaired 3 (Upd3) is one activator of the JAK-STAT pathway, and Serrate (Ser) and Jagged are ligands of the Notch receptor. Their specific roles in the niche remain little understood. (C) Schematic representation of the quiescent LT-HSCs and primed (activated) ST-HSCs and their niches in mammalian bone marrow. Signalling pathways involved in the communication between HSCs and their niches are indicated. Common lymphoid and common myeloid precursors are indicated as CLP and CMP, respectively. Curved arrows indicate cell-autonomous effects within the PSC (B) or in LT-HTCs (C).](DMM0007351F1){#f1-0040439}

The mature *Drosophila* LG is composed of a pair of anterior (primary) lobes, and several small posterior (secondary) lobes, which contain immature pro-haemocytes. The primary lobes are organised into a medullary zone (MZ) composed of pro-haemocytes, a cortical zone (CZ) containing differentiated haemocytes, and the so-called posterior signalling centre (PSC) (see below for details) ([@b38-0040439]; [@b31-0040439]) ([Fig. 1B](#f1-0040439){ref-type="fig"}). A pool of mitotically active intermediate progenitors appears at the onset of haemocyte differentiation and accounts for the increasing number of differentiated haemocytes in the mature LG ([@b34-0040439]; [@b35-0040439]). The PSC cells were initially identified by their expression of the Notch ligand Serrate (Ser) ([@b38-0040439]). A turning point in the use of *Drosophila* as a model for haematopoiesis and haematopoietic disorders was the discovery that the PSC plays a key function in controlling larval blood cell homeostasis ([@b33-0040439]; [@b45-0040439]). Specifically, the PSC cells act in a non-cell-autonomous manner to maintain the activity of the Hedgehog (Hh) and JAK-STAT signalling pathways in pro-haemocytes, thereby preserving their multipotent character. This key role of the PSC in supporting *Drosophila* blood cell homeostasis revealed unanticipated parallels with the HSC niche in mammalian bone marrow ([@b33-0040439]; [@b45-0040439]).

*Drosophila* as a model to study the haematopoietic niche
=========================================================

The concept that the niche can provide structural and trophic support as well as appropriate signals to regulate stem cell function was first proposed from work on haematopoiesis ([@b62-0040439]), but it gained strong experimental and conceptual support from studies in *Drosophila* germline stem cells ([@b76-0040439]). Recent studies indicate that detailed characterisation of stem-cell--niche interactions will help to understand the pathology of human cancers such as acute myeloid leukaemia (AML) (Box 1). Despite intensive HSC studies in humans and in vertebrate models, characterisation of the HSC niche has progressed slowly, mainly owing to the complex anatomy of bone marrow. Recent data have led to a model in which quiescent and primed stem cells interact with two different microenvironments: the endosteal surface covered by immature osteoblasts (the 'osteoblastic niche'), which favours long-term quiescence, and the sinusoidal vessels of the central bone marrow (the 'vascular niche'), which favours proliferation of HSCs ([Fig. 1C](#f1-0040439){ref-type="fig"}) ([@b70-0040439]). The vessels and endosteal surfaces are intimately entwined within trabecular bone and might play a coordinated and interrelated role, rather than having binary functions.

###### Understanding the hematopoietic niche supports studies of cancer

Seminal studies of acute myeloid leukaemia (AML), an aggressive malignancy of immature haematopoietic cells in the bone marrow, suggested that AML 'leukaemic stem cells' (LSCs) arose from HSCs ([@b5-0040439]; [@b59-0040439]). This led to the cancer stem cell (CSC) hypothesis that proposed that many human cancers are organised in cellular hierarchies, similar to normal tissues. At the hierarchy apex are multipotent, largely quiescent, long-lived CSCs with self-renewal capacity that sustain disease ([@b5-0040439]). Investigation of a large number of human AML samples has recently shown that haematopoietic progenitors, rather than HSCs, could be the origin of LSCs. The most important aspect is the ability of LSCs to self-renew, a crucial property of stem cells ([@b23-0040439]; [@b43-0040439]). Mouse xenograft models of acute lymphoblastic leukaemia (ALL) recently showed that leukaemic proliferation in bone marrow alters the stromal microenvironment and creates 'malignant niches' that out-compete native HSCs. Normal HSCs engaged by the malignant niche exhibit abnormal behaviour, and AML LSCs that home to and engraft within the osteoblastic niche are protected from chemotherapy-induced apoptosis. These findings raise many questions about the nature of the dysfunction of stem and/or progenitor cells and their niche in cancer, as well as related questions about therapy selection and/or intensification ([@b11-0040439]).

Genetic, transgenic and molecular studies in mice that made use of promoters and inducible systems that are specific to the osteoblastic lineage have uncovered several signalling pathways that are involved in the communication between HSCs and their niche(s) ([Table 1](#t1-0040439){ref-type="table"} and [Fig. 1C](#f1-0040439){ref-type="fig"}). In brief, dormant HSCs and osteoblasts bind via homotypic N-cadherin interactions. Expression of angiopoietin-1 and osteopontin by osteoblasts contributes to both the adhesion of HSCs to the osteoblastic niche and to HSC quiescence ([@b1-0040439]; [@b51-0040439]). Enforced expression of the Wnt inhibitor Dickkopf1 in osteoblasts showed that Wnt pathway activation in the niche is required to limit HSC proliferation and thereby to preserve HSC self-renewal capacity and longevity following repeated expansion ([@b20-0040439]). Parathyroid hormone (PTH) signalling in osteoblasts leads to an increased number of HSCs, probably mediated through high expression levels of the Notch ligand Jagged1 in osteoblasts ([@b8-0040439]). Conversely, signalling by bone morphogenic proteins (BMPs) controls the number of HSCs by regulating the number of osteoblastic cells ([@b78-0040439]). Finally, CXC-chemokine ligand 12 (CXCL12) produced by the reticular cells \[CXCL12-abundant reticular (CAR) cells\] surrounding the sinusoidal endothelial cells is required for maintaining the primed HSC pool. The interconnections between Wnt, PTH, CXCL12 and Notch signalling, however, remain unclear.

Despite the tremendous amount of information gathered from these investigations, our knowledge about the niche and its function remains fragmentary. New approaches are necessary to determine how the integration of different signalling pathways in the niche maintains HSCs. Many transcriptional regulators and signalling pathways involved in haematopoiesis are conserved between humans and *Drosophila* ([Table 1](#t1-0040439){ref-type="table"} and [Fig. 1B,C](#f1-0040439){ref-type="fig"}). Therefore, the *Drosophila* PSC, which controls the differentiation of pro-haemocytes in a non-cell-autonomous manner, represents an interesting, genetically tractable model with which to study signal integration and crosstalk during blood cell development.

PSC cells are specified in the embryo by the expression of two transcription factors, the homeotic protein Antennapedia (Antp) and Collier (Col), the *Drosophila* orthologue of early B-cell factors (EBFs) ([@b13-0040439]; [@b45-0040439]). In the absence of Col activity, the PSC is not specified and larval pro-haemocytes are not maintained, and differentiate prematurely. Mouse EBF2 was recently shown to act in osteoblastic cells and to regulate the maintenance of HSCs, in part by modulating Wnt signalling ([@b32-0040439]). This finding is particularly interesting given that Wingless (Wg; the *Drosophila* orthologue of Wnt) signalling has been shown to control both the number of PSC cells and the maintenance of pro-haemocytes ([@b64-0040439]). PSC cells also express the morphogen Hh, and Hh signalling is required to maintain haemocyte homeostasis in the LG ([@b45-0040439]). Finally, Ser-mediated Notch signalling from the PSC is required to maintain normal Col expression levels and activity in the PSC ([@b33-0040439]) ([Fig. 1B](#f1-0040439){ref-type="fig"}). How Hh, Wg, Notch and other signalling outputs are integrated in PSC cells to control JAK-STAT signalling activity in pro-haemocytes and to control blood homeostasis is now being addressed in several laboratories. Our recent studies of the LG have uncovered a previously unidentified mode by which JAK-STAT signalling is regulated, involving a non-signalling dominant-negative form of a cytokine receptor ([@b44-0040439]). Ongoing characterisation and genetic manipulation of PSC function in controlling *Drosophila* haematopoiesis are thus expected to provide clues as to how the mammalian bone marrow niche controls the balance between HSC self-renewal and differentiation.

ROS levels in regulating haematopoiesis: a *Drosophila* case
============================================================

The functional difference between the osteoblastic and vascular niches in mouse bone marrow might be related to oxygen availability: oxygen levels are probably higher in the vascular niche, whereas the LT-HSC osteoblastic niche is hypoxic ([@b55-0040439]; [@b63-0040439]). A low-oxygen microenvironment could be essential for the maintenance of HSCs and for their protection from detrimental ROS accumulation ([@b30-0040439]), whereas a high-oxygen microenvironment could favour proliferation (for a review, see [@b19-0040439]). Notably, the forkhead O (FoxO) transcription factors play essential roles in preserving quiescence and enhancing survival of HSCs in the bone marrow through regulating the response to physiological oxidative stress ([@b69-0040439]), although how this regulation is exerted remains poorly understood. The distinct metabolism of HSCs \[and probably also leukaemic stem cells (Box 1)\], which utilise glycolysis instead of mitochondrial oxidative phosphorylation, does indeed reflect their location in a hypoxic niche ([@b63-0040439]). Notably, quiescent leukaemic cells that reside in the hypoxic endosteum are resistant to radio- and chemotherapy ([@b29-0040439]; [@b60-0040439]). The link between ROS levels and HSC survival therefore contributes to understanding the connection between ROS levels in cancer stem cells (Box 1) and the resistance of tumours to radiation ([@b14-0040439]).

###### 

Conserved proteins with important roles in haematopoiesis

                                                                                     ***Drosophila* function**                                                                                         **Mammalian function**
  ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  **Transcription factors and cofactors[^a^](#tfn1-0040439){ref-type="table-fn"}**                                                                                                                     
  Srp (GATA)                                                                         Specification of haemocytes; progenitor maintenance ([@b37-0040439]; [@b38-0040439]; [@b68-0040439])              Maintenance of HSCs; lineage commitment; regulation of differentiation ([@b52-0040439]; [@b6-0040439])
                                                                                                                                                                                                       
  Lz (RUNX)                                                                          Specification of haemocytes ([@b37-0040439]; [@b38-0040439])                                                      Maintenance of HSCs; lineage commitment; regulation of differentiation ([@b73-0040439])
                                                                                                                                                                                                       
  Ush (FOG)                                                                          Specification of haemocytes; differentiation of lamellocytes ([@b37-0040439]; [@b66-0040439])                     Lineage commitment; regulation of differentiation ([@b71-0040439])
                                                                                                                                                                                                       
  Col (EBF)                                                                          Maintenance of PSC cells ([@b13-0040439]; [@b33-0040439])                                                         B-cell differentiation; maintenance of the niche ([@b40-0040439]; [@b32-0040439])
                                                                                                                                                                                                       
  Antp (HOX)                                                                         Formation of the PSC ([@b31-0040439])                                                                             HSC proliferation and self-renewal; myelopoiesis; B lymphopoiesis ([@b2-0040439])
  **Signalling pathways[^a^](#tfn1-0040439){ref-type="table-fn"}**                                                                                                                                     
  Notch                                                                              Differentiation of crystal cells ([@b38-0040439])                                                                 Maintenance of HSCs; haematopoietic regeneration; regulation of differentiation ([@b74-0040439]; [@b58-0040439])
                                                                                                                                                                                                       
  Hedgehog                                                                           Maintenance of pro-haemocytes ([@b45-0040439])                                                                    Lineage commitment; regulation of differentiation ([@b26-0040439]; [@b9-0040439]; [@b21-0040439])
                                                                                                                                                                                                       
  Wingless (WNT)                                                                     Proliferation of PSC cells; maintenance of pro-haemocytes; differentiation of crystal cells ([@b64-0040439])      Maintenance and proliferation of HSCs; regulation of B- and T-cell differentiation ([@b24-0040439])
                                                                                                                                                                                                       
  JAK-STAT                                                                           Maintenance of pro-haemocytes; differentiation of lamellocytes ([@b33-0040439]; [@b25-0040439]; [@b42-0040439])   HSC renewal during regeneration; lineage commitment ([@b10-0040439])
                                                                                                                                                                                                       
  ROS/FoxO                                                                           Maintenance of pro-haemocytes ([@b54-0040439])                                                                    Maintenance of HSCs; differentiation of erythroid cells ([@b69-0040439])
                                                                                                                                                                                                       
  Pvf (PDGF/VEGF)                                                                    Differentiation of plasmatocytes ([@b31-0040439])                                                                 Maintenance of HSCs (VEGF) ([@b22-0040439])

Mammalian genetic or functional homologues are shown in parentheses.

Owusu-Hansa and Banerjee ([@b54-0040439]) established the role of ROS in the control of *Drosophila* haematopoiesis, revealing that the accumulation of ROS in the LG is tightly controlled during development. This report showed that ROS levels in pro-haemocytes are an intrinsic factor that sensitises these progenitors to differentiation. Furthermore, they found that there is a tight correlation between FoxO overactivation and the downregulation of Polycomb (an epigenetic silencer) in cells with high ROS levels; this is in agreement with a previous report that showed that repressing the activity of a Polycomb protein provoked abnormal lamellocyte differentiation ([@b57-0040439]). *Drosophila* haematopoiesis is thus an excellent model in which to study the tight developmental control of ROS levels that might play a key role in the transition from HSCs to myeloid progenitors in mammals ([@b69-0040439]). Similar studies might also be useful for dissecting how signalling via ROS is connected to other signalling pathways, such as the Wg and JAK-STAT pathways required for pro-haemocyte maintenance in the LG ([@b64-0040439]; [@b44-0040439]). This would provide a more integrated view of how haematopoiesis is controlled in different environmental conditions.

Using *Drosophila* to identify new oncogene partners
====================================================

*Drosophila* can provide a valuable in vivo screening platform for modifiers, enhancers or suppressors of human oncogenic protein function, as illustrated by studies of AML. The pathogenesis of AML is considered to involve multistep genetic alterations in several genes that predispose or promote leukaemias \[for a recent WHO classification, see Dohner et al. ([@b15-0040439])\]. Analyses of chromosomal translocations in the bone marrow of AML patients have shown that several transcription factors that are crucial for haematopoiesis also play important roles in leukaemogenesis. These include AML1, LMO2, SALL, MLL and SCl/Tal1, all of which are proteins with clearly identified *Drosophila* orthologues (FlyBase; <http://flybase.org/>).

The *t(8;21) (q22;q22)* chromosomal translocation, which creates the AML1-ETO fusion product (see below), is found in ∼12% of AML patients. Under normal conditions, AML1, a RUNX-domain protein, acts as a tissue-specific transcriptional activator at multiple steps during haematopoiesis, whereas ETO (also known as RUNX1T1 and MTG8) functions as a transcriptional repressor. The commonly accepted view is that the AML1-ETO fusion product acts as a constitutive repressor of AML1 protein function and inhibits myeloid differentiation while promoting proliferation of multilineage progenitors. Interestingly, the *Drosophila* RUNX protein Lozenge is required for the differentiation of crystal cells. Two independent groups expressed human AML1-ETO in *Drosophila* haemocyte precursors and showed that this results in increased proliferation of circulating progenitors, the formation of 'melanotic tumours' or 'pseudotumours' and prevention of crystal cell differentiation. Both groups then performed genetic screens to identify modifiers of these blood phenotypes, which could potentially be modulators of the human leukaemogenic protein. One group revealed that mutations in components of the Wnt4-Frizzled and Ca^2+^ signalling pathways increased AML1-ETO activity ([@b65-0040439]). The other group identified eight suppressor candidates, including Calpain B (CalpB), a Ca^2+^-dependent protease ([@b53-0040439]). Functional analysis of CalpB revealed that it is required to stabilize AML1-ETO in the nucleus. Interestingly, CalpB was also found to interact with AML1-ETO in human cells ([@b53-0040439]), opening up the possibility that it might have a role in regulating leukaemogenesis. This functional study provides proof of principle that expression of human oncogenic factors in *Drosophila* haemocytes can help to identify core regulatory networks whose dysregulation in humans contributes to the development of leukaemias.

###### Advantages of *Drosophila* as a model for haematopoiesis and leukaemias

-   *Drosophila* is amenable to genetic and transgenic manipulations. Homologous recombination and targeted RNAi technologies are routinely used, both in vivo and in cell culture assays. Large collections of mutants and double-stranded RNA (dsRNA) libraries are available.

-   *Drosophila* has a very short generation time and is easy to maintain in large populations that are convenient for large-scale genetic screens as well as transcriptome, proteome and interactome analyses.

-   The genomic sequences of 12 *Drosophila* species and of several Diptera of medical interest (mosquitoes) are available. This allows a high precision of sequence comparison of coding and regulatory regions between these species and mutants, or of variants within a given species.

-   The problem of functional redundancy that is often encountered when studying human genes owing to vertebrate genome duplications is minimised in *Drosophila*.

-   *Drosophila* models of leukaemia created by expressing human oncogenic or abnormal proteins can be used to search for new genetic regulators.

As noted above, AML1-ETO expression in *Drosophila* provokes an increased proliferation of haemocyte precursors and the formation of melanotic tumours or pseudotumours ([@b53-0040439]; [@b65-0040439]). Such tumours were previously observed in a gain-of-function mutation affecting the kinase domain of the Hopscotch kinase (Hop^tuml^ mutation), the *Drosophila* JAK-STAT kinase ([@b25-0040439]; [@b42-0040439]). Furthermore, misexpression of a dominant-active form of the transcriptional effector of the pathway, STAT92E (STAT92E^ΔNΔC^ mutation) also promotes tumorigenesis ([@b18-0040439]). Together with the key role of JAK-STAT signalling in the maintenance of pro-haemocytes in the LG ([@b44-0040439]), these tumorous phenotypes could be particularly relevant to the study of human leukaemias, because mutations and translocations of JAK genes are associated with a variety of haematopoietic malignancies ([@b7-0040439]; [@b72-0040439]; [@b50-0040439]). For example, an activating mutation in the human tyrosine kinase JAK2 (JAK2V617F) is responsible for various forms of myeloid leukaemia. Mouse models have confirmed that this mutation causes myeloproliferative neoplasms and has differential effects on HSCs and myeloid progenitor cells ([@b39-0040439]; [@b50-0040439]; [@b49-0040439]). It is therefore possible that the constitutive activity of conserved components of the JAK-STAT pathway can be used in RNAi screens to identify in vivo suppressors of JAK-STAT activity. Such suppressors might have conserved functions in restricting acute lymphoblastic leukaemia (ALL) or AML progression in humans and could provide potential targets for therapeutic intervention.

Conclusions
===========

For the past 30 years, *Drosophila melanogaster* has been a central model for understanding the genetic and molecular bases of animal development. During this period, new genetic and genomic resources and technologies have been developed that allow tissue-specific knockdown of gene expression, gene replacement and site-specific integration of modified and/or exogenous genes in the *Drosophila* genome. The recent description of *Drosophila* haematopoietic stem-like cells and their niche -- and the accumulating evidence that many of the basic pathways and processes are also present in vertebrates -- establishes *Drosophila* as a model for studying the genetic aspects of haematopoiesis and haematopoietic disorders.

A new repressible binary expression system for transgene expression, the Q system, has recently been developed ([@b56-0040439]). The combination of the Q system and the previously established GAL4 inducible system will allow the development of strategies for manipulating transgene expression in different cell types in the same fly. This opens the prospect of manipulating gene expression and/or signalling activities in vivo, simultaneously in HSCs and niche cells, and decrypting their reciprocal communication under physiological and pathological conditions. Large-scale screens for melanotic-tumour suppressor genes have already been performed, and new genes and gene networks controlling blood cell homeostasis have been identified ([@b47-0040439]; [@b67-0040439]; [@b3-0040439]; [@b4-0040439]; [@b48-0040439]). On the basis of these pioneering experiments, and the recent demonstration that *Drosophila* can be used to identify the core regulatory network that contributes to the development of AML ([@b53-0040439]; [@b65-0040439]), it is expected that more genetic screens performed in flies will provide novel entries to the study of acute and chronic leukaemias in mammals.
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